Art. -Nr.: HY-13750

Ebselen

(Synonyms: SPI-1005; PZ-51; CCG-39161)

27 Cited Publications

Kundenbewertung

Based on 27 publication(s) in Google Scholar

Ebselen (SPI-1005), a glutathione peroxidase mimetic, is a potent voltage-dependent calcium channel (VDCC) blocker. Ebselen potently inhibits M^pro (IC₅₀=0.67 μM) and COVID-19 virus (EC₅₀=4.67 μM).Ebselen is an inhibitor of HIV-1 capsid CTD dimerization. Ebselen, an organoselenium compound, can permeate the blood-brain barrier and has anti-inflammatory, antioxidant and anticancer activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.80%
CAS. Nr.: 60940-34-3
Formel: C₁₃H₉NOSe
Molecular Weight:274.18

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Ebselen Chemical Structure

CAS. Nr.: 60940-34-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (27)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Ebselen (SPI-1005), a glutathione peroxidase mimetic, is a potent voltage-dependent calcium channel (VDCC) blocker^[1]^[2]. Ebselen potently inhibits M^pro (IC₅₀=0.67 μM) and COVID-19 virus (EC₅₀=4.67 μM)^[3].Ebselen is an inhibitor of HIV-1 capsid CTD dimerization. Ebselen, an organoselenium compound, can permeate the blood-brain barrier and has anti-inflammatory, antioxidant and anticancer activity^[4]^[5].

IC₅₀ & Target

HIV-1

Alle Calcium Channel Isoform-spezifische Produkte anzeigen :

Alle HIV Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
184B5	GI₅₀	30.1 μM Compound: EBS	Antiproliferative activity against human 184B5 cells after 72 hrs by MTT assay Antiproliferative activity against human 184B5 cells after 72 hrs by MTT assay	[PMID: 30071406]
A549	IC₅₀	>100 μM Compound: PZ51	Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25817772]
A549	IC₅₀	>50 μM Compound: EBS	Cytotoxicity against human A549 cells measured after 24 to 72 hrs by MTT assay Cytotoxicity against human A549 cells measured after 24 to 72 hrs by MTT assay	[PMID: 37482018]
A549	IC₅₀	16.8 μM Compound: Ebs	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based assay	[PMID: 29584939]
A549	IC₅₀	3.75 μM Compound: Ebselen	Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay	[PMID: 22483583]
BEAS-2B	GI₅₀	49.5 μM Compound: EBS	Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay	[PMID: 30071406]
Bel-7402	IC₅₀	68.2 μM Compound: PZ51	Antiproliferative activity against human Bel7402 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human Bel7402 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25817772]
BGC-823	IC₅₀	>50 μM Compound: EBS	Cytotoxicity against human BGC-823 cells measured after 24 to 72 hrs by MTT assay Cytotoxicity against human BGC-823 cells measured after 24 to 72 hrs by MTT assay	[PMID: 37482018]
Calu-1	GI₅₀	68.6 μM Compound: EBS	Antiproliferative activity against human HTB-54 cells after 72 hrs by MTT assay Antiproliferative activity against human HTB-54 cells after 72 hrs by MTT assay	[PMID: 30071406]
CCRF-CEM	GI₅₀	57.1 μM Compound: EBS	Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay	[PMID: 30071406]
CHO-K1	EC₅₀	6.1 μM Compound: 7	Cytotoxicity against CHO-K1 cells by Alamar blue assay Cytotoxicity against CHO-K1 cells by Alamar blue assay	[PMID: 16962325]
HaCaT	IC₅₀	>32 μM Compound: 2a	Cytotoxicity against human HaCaT cells Cytotoxicity against human HaCaT cells	[PMID: 35099959]
HCT-116	IC₅₀	50 μM Compound: Ebs	Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based assay Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based assay	[PMID: 29584939]
HeLa	IC₅₀	>50 μM Compound: EBS	Cytotoxicity against human HeLa cells measured after 24 to 72 hrs by MTT assay Cytotoxicity against human HeLa cells measured after 24 to 72 hrs by MTT assay	[PMID: 37482018]
HeLa	IC₅₀	78.5 μM Compound: PZ51	Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25817772]
HT-29	GI₅₀	>100 μM Compound: EBS	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 30071406]
HT-29	IC₅₀	50.4 μM Compound: Ebs	Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based assay Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based assay	[PMID: 29584939]
MCF7	GI₅₀	58.8 μM Compound: EBS	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30071406]
MCF7	IC₅₀	>100 μM Compound: PZ51	Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25817772]
MCF7	IC₅₀	>50 μM Compound: EBS	Cytotoxicity against human MCF7 cells measured after 24 to 72 hrs by MTT assay Cytotoxicity against human MCF7 cells measured after 24 to 72 hrs by MTT assay	[PMID: 37482018]
MCF7	IC₅₀	15.02 μM Compound: Ebselen	Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay	[PMID: 22483583]
MDA-MB-231	IC₅₀	42.3 μM Compound: 1, PZ 51, ebselen	Antiproliferative activity against human MDA231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA231 cells after 72 hrs by MTT assay	[PMID: 22204902]
NCI-H1299	IC₅₀	27.7 μM Compound: Ebs	Cytotoxicity in human NCI-H1299 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based assay Cytotoxicity in human NCI-H1299 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based assay	[PMID: 29584939]
PC-3	GI₅₀	>100 μM Compound: EBS	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 30071406]
SW480	IC₅₀	>50 μM Compound: EBS	Cytotoxicity against human SW480 cells measured after 24 to 72 hrs by MTT assay Cytotoxicity against human SW480 cells measured after 24 to 72 hrs by MTT assay	[PMID: 37482018]
U-266	IC₅₀	40 μM Compound: 62	Anticancer activity against human U-266 cells assessed as cell growth inhibition incubated for 24 hrs by MTS assay Anticancer activity against human U-266 cells assessed as cell growth inhibition incubated for 24 hrs by MTS assay	[PMID: 34217061]
Vero C1008	CC₅₀	>20 μM Compound: Ebselen	Cytotoxicity against african green monkey Vero E6 cells Cytotoxicity against african green monkey Vero E6 cells	[PMID: 36475694]
Vero C1008	CC₅₀	70.5 μM Compound: Ebselen	Cytotoxicity against African green monkey Vero E6 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay	[PMID: 37972434]
Vero C1008	EC₅₀	4.67 μM Compound: 7	Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as reduction in viral replication Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as reduction in viral replication	[PMID: 37244162]
Vero C1008	EC₅₀	4.67 μM Compound: 7	Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay	[PMID: 37244162]

In Vitro

Ebselen (SPI-1005; 0.4-100 μM; 20-24 hours) shows strong antiviral effects at a concentration of 10 μM treatment in COVID-19 virus infected Vero cells. Ebsele covalently binds to C145 of the catalytic dyad in COVID-19 virus Mpro^[3].
Ebselen inhibits early viral postentry events of the HIV-1 life cycle by impairing the incoming capsid uncoating process^[4].
Ebselen permeates the blood-brain barrier and inhibits endogenous inositol monophosphatase in mouse brain. Ebselen inhibits inositol monophosphatase (IMPase)^[5].
Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic, renal cancer cell lines^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[3]

Cell Line:

COVID-19 virus infected Vero cells
Concentration:

0.4, 1.2, 3.7, 11.1, 33.3, 100 μM
Incubation Time:

20-24 hours
Result:

Showed strong antiviral effects at a concentration of 10 μM treatment.

In Vivo

Ebselen (5, 10 mg/kg; IP) decreases 5-HT₂ agonist-induced head twitches in a dose-dependent manner^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

20-25 g 10-12 week old male C57Bl6 mice^[5]
Dosage:

5, 10 mg/kg
Administration:

IP
Result:

Decreased 5-HT₂ agonist-induced head twitches in a dose-dependent manner.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 60940-34-3
Appearance Solid
Molecular Weight 274.18
Formel C₁₃H₉NOSe
Color Off-white to light yellow
SMILES

O=C1N(C2=CC=CC=C2)[Se]C3=C1C=CC=C3
Synonyms

SPI-1005; PZ-51; CCG-39161
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (27)

All Bio/Physico-chemical AssayHistological Imaging/StainingIn Vivo Efficacy StudyWB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Fructose 1-phosphate inhibits mannose phosphate isomerase to suppress hepatocellular carcinogenesis. [Abstract]

2026 May 25;11(1):195. PMID: 42178306
Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Nat Commun

PRDX1 promotes testosterone synthesis and attenuates aging via redox regulation of ATG4B to modulate lipophagy. [Abstract]

2025 Nov 19;16(1):10181. PMID: 41261096

Ebselen purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 19;16(1):10181. [Abstract]

Representative H&E images showing testis morphology of aged Ctrl and cKO mice, Ctrl and cKO mice with Ebselen (20 mg/kg/day, ip, one month) treatment, and cOE mice (conditional overexpression of PRDX1 in LCs).

Ebselen purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 19;16(1):10181. [Abstract]

We found that Ebselen (20 mg/kg/day, ip, one month) treatment effectively improved the parameters for memory, behavior, and maximal exercise capacity in both aged Ctrl and cKO mice, as revealed by the number of alternation behaviors (measured by Y-maze test), the total distance and exploratory behavior (measured by open field trail), and the time to exhaustion (measured by run-to-exhaustion test).

Ebselen purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 19;16(1):10181. [Abstract]

Both Ebselen (20 mg/kg/day, ip, one month) treatment and PRDX1 overexpression significantly increased autophagosome-LD contact.

Ebselen purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 19;16(1):10181. [Abstract]

Ebselen (20 mg/kg/day, ip, one month) treatment also increased sperm count in aged cKO mice, and both Ebselen treatment and PRDX1 overexpression greatly enhanced sperm motility.
Nat Commun

IDH status dictates oHSV mediated metabolic reprogramming affecting anti-tumor immunity. [Abstract]

2025 Apr 24;16(1):3874. PMID: 40274791

Ebselen purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Apr 24;16(1):3874. [Abstract]

Treatment of both GBM12 and GBM28 cells with ROS scavenger, Ebselen (25 μM) also reduced virus-induced lipid peroxidation.
Redox Biol

Ebselen improves fungal keratitis through exerting anti-inflammation, anti-oxidative stress, and antifungal effects. [Abstract]

2024 May 23:73:103206. PMID: 38796864
Biomaterials

Ru(II)-modified TiO2 nanoparticles for hypoxia-adaptive photo-immunotherapy of oral squamous cell carcinoma. [Abstract]

2022 Oct:289:121757. PMID: 36058028
Environ Int

Zinc oxide/graphene oxide nanocomposites efficiently inhibited cadmium-induced hepatotoxicity via releasing Zn ions and up-regulating MRP1 expression. [Abstract]

2022 Jul:165:107327. PMID: 35667343
Free Radic Biol Med

GPX3 activates autophagy to protect cochlear spiral ganglion neurons from injury in age-related hearing loss. [Abstract]

2026 Mar 16:250:16-29. PMID: 41850409
Anal Chim Acta

A novel Zn2+ probe for fluorescent monitoring of drug and E6/E7 protein interaction in living cells. [Abstract]

2025 Aug 15:1363:344202. PMID: 40480729
Int Immunopharmacol

Ebselen's role in overcoming cisplatin resistance in colorectal Cancer via SQSTM1 ubiquitination modulation. [Abstract]

2026 Jul 15:181:116705. PMID: 42085841
J Enzyme Inhib Med Chem

Natural product sennoside B disrupts liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein by inhibiting its RNA-binding activity. [Abstract]

2025 Dec;40(1):2501743. PMID: 40371698
J Enzyme Inhib Med Chem

The selenium-containing drug ebselen potently disrupts LEDGF/p75-HIV-1 integrase interaction by targeting LEDGF/p75. [Abstract]

2020 Dec;35(1):906-912. PMID: 32228103
Int J Antimicrob Agents

Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro. [Abstract]

2019 Dec;54(6):814-819. PMID: 31479744
Sci Rep

Cysteine-reactive mitigators of small vessel disease-related NOTCH3 mutants. [Abstract]

2026 Mar 20;16(1):14300. PMID: 41862552
Sci Rep

Broad-spectrum antiviral activity of ebselen. [Abstract]

2025 Dec 29;15(1):44762. PMID: 41461699
Transplantation

Targeted Restoration of GPX3 Attenuates Renal Ischemia/Reperfusion Injury by Balancing Selenoprotein Expression and Inhibiting ROS-mediated Mitochondrial Apoptosis. [Abstract]

2024 May 21. PMID: 38771110
Mol Cell Biochem

Ebselen ameliorates renal ischemia-reperfusion injury via enhancing autophagy in rats. [Abstract]

2022 Jun;477(6):1873-1885. PMID: 35338455
iScience

Phospho-JNK agonists show promising effects for the treatment of hepatocellular carcinoma. [Abstract]

2026 May 20;29(6):116005. PMID: 42211113
Antiviral Res

Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2. [Abstract]

2023 Jun:214:105606. PMID: 37076089
Biol Trace Elem Res

Selenoprotein Gene mRNA Expression Evaluation During Renal Ischemia-Reperfusion Injury in Rats and Ebselen Intervention Effects. [Abstract]

2023 Apr;201(4):1792-1805. PMID: 35553364
Antiviral Res

A HTRF based competitive binding assay for screening specific inhibitors of HIV-1 capsid assembly targeting the C-Terminal domain of capsid. [Abstract]

2019 Sep:169:104544. PMID: 31254557
SLAS Discov

A Novel Flow Cytometric Assay to Identify Inhibitors of RBPJ-DNA Interactions. [Abstract]

2020 Sep;25(8):895-905. PMID: 32567455
Behav Brain Res

Ebselen alleviates white matter lesions and improves cognitive deficits by attenuating oxidative stress via Keap1/Nrf2 pathway in chronic cerebral hypoperfusion mice. [Abstract]

2023 Jun 25:448:114444. PMID: 37098387
Exp Ther Med

Ebselen protects rat hearts against myocardial ischemia-reperfusion injury. [Abstract]

2019 Feb;17(2):1412-1419. PMID: 30680022

Ebselen purchased from MedChemExpress. Usage Cited in: Exp Ther Med. 2019 Feb;17(2):1412-1419. [Abstract]

Ebselen influences the expression of apoptosis‑related proteins. The effects of ebselen on C‑Caspase‑8, C‑Caspase‑3, Bax, Bcl‑2 and C‑PARP are analyzed by western blotting.
Vet Med Sci

Ebselen Alleviates Sepsis-Induced Acute Kidney Injury by Regulating Endoplasmic Reticulum Stress, Apoptosis, and Oxidative Stress. [Abstract]

2025 Mar;11(2):e70318. PMID: 40116632
bioRxiv

2025 Nov 17.
University of Nebraska

2025.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (182.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.6472 mL

18.2361 mL

36.4723 mL

5 mM

0.7294 mL

3.6472 mL

7.2945 mL

10 mM

0.3647 mL

1.8236 mL

3.6472 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (789 KB)
- English - EN (789 KB)
- Français - FR (789 KB)
- Deutsch - DE (789 KB)
- Norwegian - NO (789 KB)
- Español - ES (789 KB)
- Swedish - SV (789 KB)
- Italian - IT (789 KB)
- Korean - KR (789 KB)
- Portuguese - PT (789 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Liang Q, et al. Electrical Stimulation Degenerated Cochlear Synapses Through Oxidative Stress in NeonatalCochlear Explants. Front Neurosci. 2019 Oct 14;13:1073. [Content Brief]

[2]. H Sies, et al. Ebselen, a Selenoorganic Compound as Glutathione Peroxidase Mimic [Content Brief]

[3]. Jin Z, et al. Structure of M^pro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9. [Content Brief]

[4]. Thenin-Houssier S, et al. Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2195-208. [Content Brief]

[5]. Singh N, et al. A safe lithium mimetic for bipolar disorder. Nat Commun. 2013;4:1332. doi: 10.1038/ncomms2320. [Content Brief]

[6]. Hanavan PD, et al. Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic and renal cancer cell lines. Oncotarget. 2015 Jul 30;6(21):18418-28. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.6472 mL	18.2361 mL	36.4723 mL	91.1806 mL
	5 mM	0.7294 mL	3.6472 mL	7.2945 mL	18.2361 mL
	10 mM	0.3647 mL	1.8236 mL	3.6472 mL	9.1181 mL
	15 mM	0.2431 mL	1.2157 mL	2.4315 mL	6.0787 mL
	20 mM	0.1824 mL	0.9118 mL	1.8236 mL	4.5590 mL
	25 mM	0.1459 mL	0.7294 mL	1.4589 mL	3.6472 mL
	30 mM	0.1216 mL	0.6079 mL	1.2157 mL	3.0394 mL
	40 mM	0.0912 mL	0.4559 mL	0.9118 mL	2.2795 mL
	50 mM	0.0729 mL	0.3647 mL	0.7294 mL	1.8236 mL
	60 mM	0.0608 mL	0.3039 mL	0.6079 mL	1.5197 mL
	80 mM	0.0456 mL	0.2280 mL	0.4559 mL	1.1398 mL
	100 mM	0.0365 mL	0.1824 mL	0.3647 mL	0.9118 mL

Ebselen

27 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Ebselen

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-COVID-19 Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Phosphatase Inhibitor Library

Mechanoreceptors Compound Library

Rare Diseases Drug Library

Calcium Channel Blocker Library

FDA-Approved Anticancer Drug Library

Non-steroidal Anti-Inflammatory Compound Library

Cuproptosis Compound Library

Off-patent Drug Library

Antihypertensive Compound Library

Metabolic Enzyme Compound Library

Protease Inhibitor Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Mitochondrial Toxicity Compound Library

Ion Channel Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Fibrosis Compound Library

High-Throughput Bioactive Compound Library

RNA Binding Bioactive Compound Library

MCE Kinase Hinge Binder Fragment Library

Publications Citing Use of MedChemExpress (MCE) Ebselen

Alle Calcium Channel Isoform-spezifische Produkte anzeigen

Alle HIV Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (27)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Ebselen Related Classifications

HY-13750 Related Classifications